16.50
전일 마감가:
$16.77
열려 있는:
$16.5
하루 거래량:
34,847
Relative Volume:
0.12
시가총액:
$810.39M
수익:
-
순이익/손실:
$-85.21M
주가수익비율:
-8.7302
EPS:
-1.89
순현금흐름:
$-68.53M
1주 성능:
-1.73%
1개월 성능:
-6.76%
6개월 성능:
-32.48%
1년 성능:
-27.90%
Enliven Therapeutics Inc Stock (ELVN) Company Profile
명칭
Enliven Therapeutics Inc
전화
720-647-8519
주소
6200 LOOKOUT ROAD, BOULDER
ELVN을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
ELVN
Enliven Therapeutics Inc
|
16.52 | 874.41M | 0 | -85.21M | -68.53M | -1.89 |
![]()
ONC
Beigene Ltd Adr
|
241.10 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
432.56 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.33 | 42.47M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
586.19 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
73.18 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-12-13 | 개시 | BTIG Research | Buy |
2024-09-09 | 개시 | H.C. Wainwright | Buy |
2024-06-11 | 개시 | Robert W. Baird | Outperform |
2024-04-09 | 개시 | Mizuho | Buy |
2023-03-29 | 개시 | Jefferies | Buy |
Enliven Therapeutics Inc 주식(ELVN)의 최신 뉴스
Enliven Therapeutics to Present at Upcoming Investor Conferences - PR Newswire
(ELVN) Proactive Strategies - news.stocktradersdaily.com
Enliven Therapeutics chief scientific officer sells $81,533 in stock - Investing.com Australia
Enliven Therapeutics chief scientific officer sells $81,533 in stock By Investing.com - Investing.com India
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Purchased by Northern Trust Corp - Defense World
HC Wainwright Issues Pessimistic Outlook for ELVN Earnings - Defense World
Jones Trading Has Lowered Expectations for Enliven Therapeutics (NASDAQ:ELVN) Stock Price - Defense World
Q1 Earnings Forecast for ELVN Issued By HC Wainwright - Defense World
HC Wainwright Raises Enliven Therapeutics (NASDAQ:ELVN) Price Target to $40.00 - Defense World
Jones Trading Lowers Price Target for Enliven Therapeutics (ELVN) | ELVN Stock News - GuruFocus
Enliven (ELVN) Stock Target Cut Amid Mixed Market Reaction | ELVN Stock News - GuruFocus
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Holdings Lifted by Price T Rowe Associates Inc. MD - Defense World
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 7.6% Following Weak Earnings - Defense World
Enliven Therapeutics Reports Q1 Results and Pipeline Progress - TipRanks
Enliven Therapeutics stock target raised to $40 at H.C. Wainwright By Investing.com - Investing.com South Africa
Enliven Therapeutics: Cash runway can fund ops through late 2027 - BizWest
Enliven Therapeutics (ELVN) Target Price Raised by HC Wainwright & Co. | ELVN Stock News - GuruFocus
Enliven Therapeutics stock target raised to $40 at H.C. Wainwright - Investing.com Australia
H.C. Wainwright Increases Price Target for Enliven (ELVN) Post Q - GuruFocus
H.C. Wainwright Increases Price Target for Enliven (ELVN) Post Q1 Report | ELVN Stock News - GuruFocus
Enliven reports positive Phase 1 trial data for ELVN-001 in CML - Investing.com Nigeria
Tower Research Capital LLC TRC Boosts Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update - PR Newswire
Enliven reports positive Phase 1 trial data for ELVN-001 in CML By Investing.com - Investing.com South Africa
Enliven Therapeutics Says ELVN-001 Shows Favorable Safety And Tolerability Profile - marketscreener.com
Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress - The Malaysian Reserve
Enliven (ELVN) Reports Positive Results from ENABLE Trial for Chronic Myeloid Leukemia | ELVN Stock News - GuruFocus
Breakthrough CML Drug ELVN-001 Achieves 44% Response Rate in Heavily Pretreated PatientsKey Data Revealed - Stock Titan
(ELVN) Investment Analysis - news.stocktradersdaily.com
Enliven Therapeutics (ELVN) Expected to Announce Earnings on Tuesday - Defense World
Wells Fargo & Company MN Has $375,000 Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Invesco Ltd. Buys 508 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Barclays PLC Has $1.45 Million Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics (NASDAQ:ELVN) Sets New 52-Week Low on Insider Selling - Defense World
JPMorgan Chase & Co. Trims Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven (ELVN) Gains Attention as EHA Data Release Approaches | - GuruFocus
Trading (ELVN) With Integrated Risk Controls - news.stocktradersdaily.com
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stake Lowered by Legal & General Group Plc - Defense World
Enliven Therapeutics chief scientific officer sells $80,365 in stock By Investing.com - Investing.com India
Enliven Therapeutics chief scientific officer sells $80,365 in stock - Investing.com Australia
Enliven Therapeutics Inc (ELVN) shows promising results - uspostnews.com
Enliven Therapeutics: Awaiting Additional Trial Data (NASDAQ:ELVN) - Seeking Alpha
Geode Capital Management LLC Acquires 12,510 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Can you now get a good deal on Enliven Therapeutics Inc’s shares? - uspostnews.com
(ELVN) Trading Report - news.stocktradersdaily.com
Vanguard Group Inc. Purchases 55,283 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stake Boosted by Wellington Management Group LLP - Defense World
KLP Kapitalforvaltning AS Makes New $97,000 Investment in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Ratios Revealed: Decoding Enliven Therapeutics Inc (ELVN)’s Financial Health - DWinneX
Corebridge Financial Inc. Trims Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics COO Anish Patel sells shares worth $120,268 By Investing.com - Investing.com India
Enliven Therapeutics Inc (ELVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Enliven Therapeutics Inc 주식 (ELVN) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Kintz Samuel | PRESIDENT AND CEO |
May 19 '25 |
Sale |
16.49 |
5,000 |
82,453 |
972,892 |
자본화:
|
볼륨(24시간):